Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1427-1434

  Odoherty, Catherine ^a   Schnabl, Matthew ^a   Spargo, Llewellyn ^b   Cleland, Leslie G ^b,c   James, Michael ^b,c   Proudman, Susanna M ^b,c   Wiese, Michael D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

DHODH; leflunomide; pharmacogenomics; polymorphism; response; rheumatoid arthritis

Indexed keywords

HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; DHODH GENE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HAPLOTYPES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84866314854     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.118     Document Type: Article

References (15)

1. Proudman SM, Keen HI, Stamp LK et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin. Arthritis Rheum. 37(2), 99-111 (2007 (Pubitemid 350198583)
2. Breedveld FC, Dayer JM. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59(11), 841-849 (2000
3. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. 159(21), 2542-2550 (1999
4. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353(9149), 259-266 (1999 (Pubitemid 29088117)
5. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
6. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137(9), 726-733 (2002 (Pubitemid 35265316)
7. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10(2), 303-309 (2009
8. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68(8), 1367-1368 (2009
9. Wiese MD, Schnabl MJ, O'Doherty D et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res. Ther. 14(4), R163 (2012
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31(3), 315-324 (1988 (Pubitemid 18091653)
11. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41(10), 1845-1850 (1998 (Pubitemid 28465539)
12. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74(4), 765-769 (2004 (Pubitemid 38420107)
13. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunology 47(2-3), 247-257 (2000 (Pubitemid 30394541)
14. Roberts LJ, Cleland LG, Thomas R, Proudman SM. Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. Med. J. Aust. 184(3), 122-125 (2006 (Pubitemid 43256913)
15. van Roon EN, Jansen TL, van De Laar MA et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: Serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4), 569-574 (2005 (Pubitemid 40469086)